The current Takeda UK portfolio comprises of the following medicines:
To download a patient information leaflet (PIL) and a summary of product characteristics (SmPC) for each medicine, simply follow the links within the table below:
If you are concerned about any of the conditions or treatments listed below please consult your General Practitioner or other healthcare professional. | ||
Actos® - pioglitazone hydrochloride | ||
Actos 15 mg, 30 mg, 45 mg Tablets | SmPC | PIL |
Adcetris®▼ - brentuximab vedotin | ||
Adcetris 50 mg powder for concentrate for solution for infusion | SmPC | PIL |
Alofisel®▼ - darvadstrocel * |
||
Alofisel 5 million cells/mL suspension for injection | ||
Amias® - candesartan cilexetil | ||
Amias 2 mg, 4 mg, 8 mg, 16 mg, 32 mg Tablets | SmPC | PIL |
Amitiza®▼- lubiprostone | ||
Amitiza 24 microgram soft capsules | SmPC | PIL |
Calcichew® Portfolio - calcium carbonate +/- cholecalciferol | ||
Calcichew 500 mg Chewable Tablets | SmPC | PIL |
Calcichew D3 Chewable Tablets | SmPC | PIL |
Calcichew Forte Chewable Tablets | SmPC | PIL |
Calcichew D3 1000 mg/800 IU Once Daily Chewable Tablets | SmPC | PIL |
Calcichew D3 500 mg/400 IU Caplets | SmPC | PIL |
Calcichew D3 Forte Chewable Tablets | SmPC | PIL |
Competact® - pioglitazone hydrochloride/metformin hydrochloride | ||
Competact 15 mg/850 mg film-coated Tablets | SmPC | PIL |
Condyline® - podophyllotoxin | ||
Condyline 0.5% w/v Cutaneous Solution | SmPC | PIL |
Edarbi® - azilsartan medoxomil potassium | ||
Edarbi 20 mg, 40 mg, 80 mg Tablets | SmPC | PIL |
Entyvio® - vedolizumab | ||
Entyvio 300 mg powder for concentrate for solution for infusion | SmPC | PIL |
Instanyl® - fentanyl citrate | ||
Instanyl 50, 100 and 200 mcg nasal spray, solution in single-dose container | SmPC | PIL |
Instanyl 50, 100 and 200 mcg/dose nasal spray | SmPC | PIL |
Matrifen® - fentanyl | ||
Matrifen 12, 25, 50, 75, 100 micrograms/hour Transdermal Patch | SmPC | PIL |
Mepact® - mifamurtide | ||
Mepact 4 mg powder for suspension for infusion | SmPC | PIL |
Ninlaro®▼ - ixazomib citrate | ||
Ninlaro 2.3 mg, 3 mg and 4 mg hard capsules | SmPC | PIL |
Prostap® SR DCS and Prostap®3 DCS - leuprorelin acetate | ||
Prostap 3 DCS 11.25 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe |
SmPC | PIL |
Prostap SR DCS 3.75 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe |
SmPC | PIL |
Protium® - pantoprazole | ||
Protium 40 mg i.v. powder for solution for injection | SmPC | PIL |
Pantoprazole 20 mg gastro-resistant tablets | SmPC | PIL |
Pantoprazole 40 mg gastro-resistant tablets | SmPC | PIL |
TachoSil® - human fibrinogen, human thrombin | ||
TachoSil sealant matrix | SmPC | PIL |
Vipdomet®▼ - alogliptin and metformin | ||
Vipdomet 12.5 mg/850 mg film-coated tablets |
SmPC | PIL |
Vipidia® - alogliptin benzoate | ||
Vipidia 6.25 mg, 12.5 mg, 25 mg film-coated tablets | SmPC | PIL |
*Alofisel is marketed by Takeda UK under license from TiGenix |
Please refer to the Summary of Product Characteristics for details on the full side-effect profile and drug interactions of the medicines refered to above. Adverse events should be reported. Reporting forms and information can be found at https:yellowcard.mhra.gov.uk/ |
"The black triangle denotes that additional monitoring is required in relation to adverse reactions. This allows quick identification of new safety information."
UK/WBC/1707/0002d(2)
Date of Preparation: June 2018